BRINGING YOU INFORMATION.  PROVIDING YOU A PLATFORM.

 

 
THE PHARMA REVIEW (JULY - AUGUST 2013)

Clinical Trials in India

Dr. D C Doval1, Sanjay Gupta2, Dr. Manoj Karwa3 & Dr. Amit Verma4

Introduction: Emergence of new diseases without effective prevention or control as well as growing ineffectiveness of available medicines pose a serious threat to mankind and may potentially be the end of road for modern medical treatments. According to WHO 2004, global burden of disease report the leading global risk for the mortality are high blood pressure (13% death globally), tobacco use (9% death globally), high blood glucose (6% death globally), physical inactivity (6% death globally), over weight and obesity (5% death globally). It is predicted that for low income countries, Non Communicable Diseases (NCD) will contribute half of the total disease burden in 2030 making HIV/AIDS a major cause of death (12%) followed by prenatal disease (6%), depression (4%) and ischemic heart disease (4%). It is also predicted that lung, stomach and liver cancer will appear as a leading causes of death in 2020. Almost 79% of all death cause by NCD occurs in low income countries. Hence there is a need to provide newer, safer and effective medicines to almost 5.6 billion people of the world in a single segment of NCD. Apart from this, emerging new infectious disease such as severe acute respiratory syndrome, ebola, avian flu, swine flu as well as antibiotic resistant strains of already known bacteria and various other diseases require the availability of newer and effective medicines on an urgent basis. 

 

Go to Content Index Page

PHARMA REVIEW - ARTICLES ARCHIVE ( COMPLETE LIST)

 

The above content is an abstract only. For the full Article please contact:
KONGPOSH Publications Pvt. Ltd.
ICS House, C-19, Commercial Complex, SDA, Opp. IIT Gate, New Delhi, India -110016
Tel.: 26855839, 9811195411
Email: kongposhpub@gmail.com, Website: http://www.kppub.com

 
 
 
 

Copyright KONGPOSH PUBLICATIONS Pvt. Ltd.